Andrew K. Joe

Oncology · 2006–2020

A researcher in the Science corpus: 7 papers; trusts 4 researchers and is trusted by 5 researchers here, as inferred from the citation graph.

Subfields

Whom Andrew K. Joe trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. I. Weinstein
  2. W. Kaelin

Who trusts Andrew K. Joe overall

  1. G. J. Yoshida
  2. James E. Bradner
  3. Arkaitz Carracedo
  4. Karen A. Ryall
  5. Meital Gabay

Papers from Andrew K. Joe's perspective

Ordered by how strongly the researchers Andrew K. Joe trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification (Science)
  2. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
  3. Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy (Nature Clinical Practice Oncology)
  4. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways (Science)
  5. Epigenetics in human disease and prospects for epigenetic therapy (Nature)
  6. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. (Journal of the National Cancer Institute)
  7. Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC (Science)
  8. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. (New England Journal of Medicine)
  9. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. (New England Journal of Medicine)
  10. The transcriptional repressor Snail promotes mammary tumor recurrence. (Cancer Cell)

Their papers